Roche unveils strong combination treatment data in lung cancer

pharmafile | November 20, 2017 | News story | Research and Development, Sales and Marketing |  Cancer, NSCLC< lung cancer, Roche, avastin, immunotherapy, pharma, tecentriq 

Roche has unveiled new Phase 3 efficacy data which showed strong findings for its immunotherapy Tecentriq (atezolizumab) in combination with Avastin and chemotherapy in the treatment of lung cancer.

The company revealed the findings of its Impower 150 trial into the use of Tecentriq, Avastin and chemotherapy in combination as a first-line treatment of people with advanced non-squamous non-small cell lung cancer (NSCLC). According to Roche, they demonstrated a “statistically significant and clinically meaningful reduction” in the risk of disease progression or death compared to Avastin and chemotherapy alone.

“We are extremely encouraged by these results and will submit these data to health authorities globally with the goal of bringing a potential new standard of care for the initial treatment of lung cancer,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development. “In addition to first-line NSCLC, we are testing the ability of Tecentriq and Avastin to enhance the potential of the immune system to combat a broad range of other cancers.”

Advertisement

The company did note that the results are “not fully mature”, with an analysis into overall survival benefit expected in the first half of 2018.

When announced alongside new data on the company’s haemophilia treatment Hemlibra – a therapy which just days ago scored US approval with the FDA – the news shook up share prices in the space, with haemophilia rivals Shire dropping 2% and AstraZeneca falling 0.5%, while Roche’s own shares rose by 5.6%.

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Roche secures CE Mark for automated latent tuberculosis blood test

Roche has received CE Mark approval for its Elecsys IGRA TB test, an automated blood …

The Gateway to Local Adoption Series

Latest content